Limits...
Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades.

Ochi N, Hotta K, Takigawa N, Oze I, Fujiwara Y, Ichihara E, Hisamoto A, Tabata M, Tanimoto M, Kiura K - PLoS ONE (2012)

Bottom Line: Regarding the time trend, while it was not statistically significant, it tended to decrease, with a 0.138% decrease per year and 2.76% decrease per two decades.The most common cause of death was febrile neutropenia without any significant time trend in its incidence over the years examined (p = 0.139).However, deaths due to febrile neutropenia as well as all causes in patients treated with non-platinum chemotherapy increased significantly (p = 0.033).

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

ABSTRACT

Introduction: Treatment-related death (TRD) remains a serious problem in small-cell lung cancer (SCLC), despite recent improvements in supportive care. However, few studies have formally assessed time trends in the proportion of TRD over the past two decades. The aim of this study was to determine the frequency and pattern of TRD over time.

Methods: We examined phase 3 trials conducted between 1990 and 2010 to address the role of systemic treatment for SCLC. The time trend was assessed using linear regression analysis.

Results: In total, 97 trials including nearly 25,000 enrolled patients were analyzed. The overall TRD proportion was 2.95%. Regarding the time trend, while it was not statistically significant, it tended to decrease, with a 0.138% decrease per year and 2.76% decrease per two decades. The most common cause of death was febrile neutropenia without any significant time trend in its incidence over the years examined (p = 0.139). However, deaths due to febrile neutropenia as well as all causes in patients treated with non-platinum chemotherapy increased significantly (p = 0.033).

Conclusions: The overall TRD rate has been low, but not negligible, in phase III trials for SCLC over the past two decades.

Show MeSH

Related in: MedlinePlus

Time trends in chemotherapeutic regimen.All analyses were weighted by sample size. A. Cisplatin-containing regimen. B. Carboplatin-containing regimen. C. Non-platinum regimen. D. CAV (cyclophosphamide, doxorubicin and vincristine)-based regimen.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3412813&req=5

pone-0042798-g003: Time trends in chemotherapeutic regimen.All analyses were weighted by sample size. A. Cisplatin-containing regimen. B. Carboplatin-containing regimen. C. Non-platinum regimen. D. CAV (cyclophosphamide, doxorubicin and vincristine)-based regimen.

Mentions: Figure 3 shows the changes in treatment regimens over the past two decades. Regarding platinum-based regimens, the proportion of cisplatin use was largely constant during the period (regression coefficient = 0.599, corresponding to a 0.599% increase per year; p = 0.549; Fig. 3A), while carboplatin (CBDCA)-containing regimens increased yearly (regression coefficient = 2.527 [2.527% increase per year]; p = 0.004; Fig. 3B). In contrast, the use of non-platinum combination regimens and that of cyclophosphamide, doxorubicin, and vincristine (CAV)-based regimens decreased significantly during the two decades, at 3.438% (p<0.001) and 3.300% (p = 0.001) per year, respectively (Fig. 3C and D).


Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades.

Ochi N, Hotta K, Takigawa N, Oze I, Fujiwara Y, Ichihara E, Hisamoto A, Tabata M, Tanimoto M, Kiura K - PLoS ONE (2012)

Time trends in chemotherapeutic regimen.All analyses were weighted by sample size. A. Cisplatin-containing regimen. B. Carboplatin-containing regimen. C. Non-platinum regimen. D. CAV (cyclophosphamide, doxorubicin and vincristine)-based regimen.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3412813&req=5

pone-0042798-g003: Time trends in chemotherapeutic regimen.All analyses were weighted by sample size. A. Cisplatin-containing regimen. B. Carboplatin-containing regimen. C. Non-platinum regimen. D. CAV (cyclophosphamide, doxorubicin and vincristine)-based regimen.
Mentions: Figure 3 shows the changes in treatment regimens over the past two decades. Regarding platinum-based regimens, the proportion of cisplatin use was largely constant during the period (regression coefficient = 0.599, corresponding to a 0.599% increase per year; p = 0.549; Fig. 3A), while carboplatin (CBDCA)-containing regimens increased yearly (regression coefficient = 2.527 [2.527% increase per year]; p = 0.004; Fig. 3B). In contrast, the use of non-platinum combination regimens and that of cyclophosphamide, doxorubicin, and vincristine (CAV)-based regimens decreased significantly during the two decades, at 3.438% (p<0.001) and 3.300% (p = 0.001) per year, respectively (Fig. 3C and D).

Bottom Line: Regarding the time trend, while it was not statistically significant, it tended to decrease, with a 0.138% decrease per year and 2.76% decrease per two decades.The most common cause of death was febrile neutropenia without any significant time trend in its incidence over the years examined (p = 0.139).However, deaths due to febrile neutropenia as well as all causes in patients treated with non-platinum chemotherapy increased significantly (p = 0.033).

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

ABSTRACT

Introduction: Treatment-related death (TRD) remains a serious problem in small-cell lung cancer (SCLC), despite recent improvements in supportive care. However, few studies have formally assessed time trends in the proportion of TRD over the past two decades. The aim of this study was to determine the frequency and pattern of TRD over time.

Methods: We examined phase 3 trials conducted between 1990 and 2010 to address the role of systemic treatment for SCLC. The time trend was assessed using linear regression analysis.

Results: In total, 97 trials including nearly 25,000 enrolled patients were analyzed. The overall TRD proportion was 2.95%. Regarding the time trend, while it was not statistically significant, it tended to decrease, with a 0.138% decrease per year and 2.76% decrease per two decades. The most common cause of death was febrile neutropenia without any significant time trend in its incidence over the years examined (p = 0.139). However, deaths due to febrile neutropenia as well as all causes in patients treated with non-platinum chemotherapy increased significantly (p = 0.033).

Conclusions: The overall TRD rate has been low, but not negligible, in phase III trials for SCLC over the past two decades.

Show MeSH
Related in: MedlinePlus